Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary NeuroMetrix Report Highlights Stigma Faced by Chronic Pain Community around Opioid Use, Desire for Alternative Treatments
84 percent of Americans living with chronic pain believe there is a stigma around opioid use; 90 percent are actively seeking alternative treatments WALTHAM, Mass. , June 21, 2018 (GLOBE NEWSWIRE) -- The opioid crisis continues to make headlines, but in the midst of this chaos, members of the
View HTML
Toggle Summary NeuroMetrix Receives $3.8M Milestone Payment Under Its Collaboration with GSK Consumer Healthcare
WALTHAM, Mass. , June 19, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO), today reported that it had achieved the first development milestone under its strategic collaboration with GSK Consumer Healthcare . A milestone payment of $3.8 Million was made by GSK.
View HTML
Toggle Summary Preliminary Results from Quell Chronic Low Back Pain Study to be Presented at World Institute of Pain World Congress
WALTHAM, Mass. , May 03, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO), today reported that preliminary results from a study of Quell ® wearable pain relief in chronic low back pain will be presented at the 9th World Congress of the World Institute of Pain in Dublin, Ireland May 9-12,
View HTML
Toggle Summary NeuroMetrix, Inc. to Participate in Upcoming Disruptive Growth & Healthcare Conference in New York City
WALTHAM, Mass. , May 01, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO), announced today that it will be participating in the 3rd annual Disruptive Growth & Healthcare Conference in New York City on May 8-9, 2018 sponsored by RHK Capital and ReedSmith.
View HTML
Toggle Summary NeuroMetrix to Present Quell Data at Upcoming American Academy of Pain Medicine Annual Meeting
WALTHAM, Mass. , April 24, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO) today reported that it will present two scientific posters at the upcoming 2018 American Academy of Pain Medicine (AAPM) Annual Meeting to be held in Vancouver, Canada , April 26-28 .
View HTML
Toggle Summary NeuroMetrix Reports Q1 2018 Financial Results
GlaxoSmithKline Collaboration is Quarter Highlight WALTHAM, Mass. , April 19, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO), today reported financial and business highlights for the quarter ended March 31, 2018 . The Company develops and markets novel therapies, based on neurostimulation
View HTML
Toggle Summary NeuroMetrix Reports Q1 2018 Financial Results
GlaxoSmithKline Collaboration is Quarter Highlight WALTHAM, Mass. , April 19, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO), today reported financial and business highlights for the quarter ended March 31, 2018 . The Company develops and markets novel therapies, based on neurostimulation
View HTML
Toggle Summary NeuroMetrix to Present Data on Quell Sleep Monitoring Technology at Upcoming American Academy of Neurology Annual Meeting
WALTHAM, Mass. , April 18, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO) today reported that it will present a scientific poster at the upcoming 2018 American Academy of Neurology (AAN) Annual Meeting to be held in Los Angeles, CA , April 21-27 .
View HTML
Toggle Summary NeuroMetrix, Inc. Announces Date for 2018 First Quarter Financial Results Conference Call
WALTHAM, Mass. , April 11, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix , Inc. (Nasdaq:NURO) announced today that it plans to issue its 2018 first quarter financial results before the opening of the market on Thursday, April 19, 2018. The Company will host a conference call at 8:00 a.m., Eastern
View HTML
Toggle Summary NeuroMetrix Reports Results of Large Clinical Study of Quell Wearable Pain Relief
WALTHAM, Mass. , April 10, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO), today reported publication of results from a clinical study of Quell® in the Journal of Pain Research .  The paper is titled “Effectiveness of fixed-site high-frequency transcutaneous electrical nerve stimulation
View HTML